Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.